Medicare Enrolled
Dr. Clifton Layman, D.O.
Internal Medicine · El Paso, TX
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Layman from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Layman?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Layman
Dr. Clifton Layman is an internal medicine specialist in El Paso, TX, with 15 years of NPI registration. Based on federal Medicare data, Dr. Layman performed 15,144 Medicare services in 2023. These records do not provide a deduplicated patient total.
Between the years covered by Open Payments, Dr. Layman received a total of $419,413 from 59 pharmaceutical and/or device companies across 639 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Layman is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 15 years of NPI registration
▲ Top 3% volume in TX
$419,413 industry payments
Medicare Practice Summary — 2023
Medicare Utilization ↗15,144
Medicare services
Top 3% in TX for internal medicine
Not available
Unique patients (not deduplicated)
$12
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Anti-nausea injection (aprepitant) | 8,710 | $1 | $9 |
| Denosumab injection (Prolia/Xgeva) | 2,280 | $18 | $71 |
| Dexamethasone injection (steroid) An injection of dexamethasone sodium phosphate, a corticosteroid medication, administered in a dose of 1 milligram. |
910 | $0 | $1 |
| Anti-nausea injection (Aloxi/palonosetron) | 890 | $1 | $122 |
| Fluorouracil injection, 500 mg Administration of a 500 mg dose of fluorouracil medication via injection. |
353 | $2 | $14 |
| Intravenous injection of additional new drug or substance Administration of an additional new medication or substance directly into a vein. |
317 | $11 | $105 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
293 | $132 | $301 |
| Injection, granisetron hydrochloride, 100 mcg | 220 | $0 | $25 |
| Intravenous chemotherapy infusion, 1 hour or less Administration of chemotherapy medication directly into a vein. The procedure takes one hour or less to complete. |
200 | $94 | $686 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
180 | $91 | $215 |
| Intravenous infusion of new drug or substance, 1 hour or less This procedure involves administering a new medication or substance directly into a vein through an existing access site. The infusion is completed within one hour or less. |
89 | $47 | $334 |
| Additional hour of intravenous chemotherapy This code represents the administration of chemotherapy medication into a vein for each additional hour beyond the initial period. |
88 | $21 | $156 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
85 | $10 | $93 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 73 | $132 | $3,938 |
| New patient office visit, complex (60-74 min) | 71 | $159 | $432 |
| Normal saline infusion, 1000 cc Administration of 1000 cc of normal saline solution into a vein. This procedure involves the intravenous delivery of a sterile saltwater solution. |
50 | $2 | $19 |
| Additional hour of intravenous hydration This code represents each additional hour of intravenous fluid administration beyond the initial hour. It is used to bill for extended hydration therapy. |
47 | $9 | $73 |
| Blood sample collection from implanted device This procedure involves drawing a blood sample directly from a medical device that has been surgically placed in the body. |
46 | $19 | $64 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
44 | $23 | $141 |
| Intravenous push injection of new drug or substance A healthcare provider injects a new medication or substance directly into a vein using a push technique. |
36 | $40 | $281 |
| IV chemotherapy initiation with community continuation Initiation of an intravenous chemotherapy infusion in a clinic using clinic supplies, with continuation of the infusion in a community setting such as home or assisted living. |
34 | $121 | $986 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
30 | $92 | $232 |
| Intravenous infusion, 1 hour or less Administration of medication or fluid directly into a vein for therapeutic, preventive, or diagnostic purposes. The procedure lasts one hour or less. |
29 | $47 | $304 |
| Diphenhydramine injection, up to 50 mg An injection of diphenhydramine hydrochloride, an antihistamine medication, administered in a dose of up to 50 milligrams. |
29 | $1 | $7 |
| Non-hormonal chemotherapy injection This procedure involves administering non-hormonal anti-neoplastic chemotherapy medication via injection into the skin or muscle tissue. |
24 | $53 | $205 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
16 | $134 | $412 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.
2.4% high complexity
92.6% medium
5.0% routine
Industry Payment Transparency
Open Payments through 2024 ↗$419,413
Total received (2018-2024)
Avg $59,916/year across 7 years
Top 0% in TX for internal medicine
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
59
Companies
639
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →
Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$201,532
2023
$129,702
2022
$79,068
2021
$8,403
2020
$37
2019
$201
2018
$470
Payments by company (2024)
AstraZeneca Pharmaceuticals LP
$121,364
E.R. Squibb & Sons, L.L.C.
$34,985
Regeneron Healthcare Solutions, Inc.
$27,240
Daiichi Sankyo Inc.
$10,634
Karyopharm Therapeutics Inc.
$5,048
Novartis Pharmaceuticals Corporation
$297
Janssen Biotech, Inc.
$213
Celgene Corporation
$192
Genmab U.S., Inc.
$182
Gilead Sciences, Inc.
$151
Exelixis Inc.
$131
Astellas Pharma US Inc
$121
Merck Sharp & Dohme LLC
$120
Genentech USA, Inc.
$87
Incyte Corporation
$86
PFIZER INC.
$66
ABBVIE INC.
$64
Takeda Pharmaceuticals U.S.A., Inc.
$55
EMD Serono, Inc.
$51
Eisai Inc.
$51
Blueprint Medicines Corporation
$43
Bayer Healthcare Pharmaceuticals Inc.
$39
JAZZ PHARMACEUTICALS INC.
$36
Mirati Therapeutics, Inc.
$36
ARRAY BIOPHARMA INC
$36
Dendreon Pharmaceuticals LLC
$30
Kite Pharma, Inc.
$25
SpringWorks Therapeutics, Inc.
$23
Acrotech Biopharma Inc.
$23
Stemline Therapeutics Inc.
$21
Tempus AI, Inc
$21
SERVIER PHARMACEUTICALS LLC
$19
GlaxoSmithKline, LLC.
$16
Fresenius Kabi USA, LLC
$14
Rigel Pharmaceuticals, Inc.
$10
Top 3 companies account for 91.1% of 2024 payments
All-time payments by company (2018-2024) ›
AstraZeneca Pharmaceuticals LP
$147,000
E.R. Squibb & Sons, L.L.C.
$142,009
Regeneron Healthcare Solutions, Inc.
$58,441
GENZYME CORPORATION
$50,154
Daiichi Sankyo Inc.
$10,687
Karyopharm Therapeutics Inc.
$5,171
Celgene Corporation
$905
Novartis Pharmaceuticals Corporation
$548
Gilead Sciences, Inc.
$528
Genentech USA, Inc.
$383
Janssen Biotech, Inc.
$308
Astellas Pharma US Inc
$263
Genmab U.S., Inc.
$206
Incyte Corporation
$199
Merck Sharp & Dohme LLC
$197
Exelixis Inc.
$168
PFIZER INC.
$158
Alexion Pharmaceuticals, Inc.
$145
JAZZ PHARMACEUTICALS INC.
$144
Mirati Therapeutics, Inc.
$134
Takeda Pharmaceuticals U.S.A., Inc.
$115
Eisai Inc.
$112
Seagen Inc.
$107
Amgen Inc.
$105
Merck Sharp & Dohme Corporation
$91
Bayer Healthcare Pharmaceuticals Inc.
$86
ABBVIE INC.
$78
ARRAY BIOPHARMA INC
$71
EMD Serono, Inc.
$67
Puma Biotechnology, Inc.
$66
Kite Pharma, Inc.
$58
Lilly USA, LLC
$51
TerSera Therapeutics LLC
$50
Blueprint Medicines Corporation
$43
Stemline Therapeutics Inc.
$41
Rigel Pharmaceuticals, Inc.
$36
SOBI, INC
$35
CTI BioPharma Corp.
$33
Ipsen Biopharmaceuticals, Inc
$32
Dendreon Pharmaceuticals LLC
$30
Bayer HealthCare Pharmaceuticals Inc.
$29
Pharmacyclics LLC, An AbbVie Company
$26
Myovant Sciences Inc.
$24
SpringWorks Therapeutics, Inc.
$23
Acrotech Biopharma Inc.
$23
Tempus AI, Inc
$21
Progenics Pharmaceuticals, Inc.
$21
SERVIER PHARMACEUTICALS LLC
$19
PUMA BIOTECHNOLOGY, INC.
$18
Kyowa Kirin, Inc.
$18
AVEO Pharmaceuticals, Inc.
$18
EISAI INC.
$17
GlaxoSmithKline, LLC.
$16
TAIHO ONCOLOGY, INC.
$16
Pharmacyclics LLC, an AbbVie Company
$16
Fresenius Kabi USA, LLC
$14
MorphoSys, US Inc.
$13
Pharmacosmos Therapeutics Inc.
$13
Taiho Oncology, Inc.
$13
Top 3 companies account for 82.8% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · ALUNBRIG · AUGTYRO · AYVAKIT · Alecensa · BELEODAQ · BOSULIF · CABOMETYX · Columvi · DARZALEX · Doptelet · ENHERTU · ERLEADA · Enhertu · Epkinly · FOTIVDA · Fabhalta · HYQVIA · ICLUSIG · IMBRUVICA · IMFINZI · INJECTAFER · INLYTA · JAKAFI · KEYTRUDA · KISQALI · KRAZATI · LIBTAYO · LONSURF · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · MONJUVI · MONOFERRIC · NERLYNX · Nplate · Nubeqa · OGSIVEO · OJJAARA · ONIVYDE · OPDIVO · OPDUALAG · ORGOVYX · Orserdu · PLUVICTO · POTELIGEO · PROMACTA · PROVENGE · PYLARIFY · Perjeta · REBLOZYL · RETEVMO · RYBREVANT · Rezlidhia · SARCLISA · SCEMBLIX · Stimufend · Stivarga · TAGRISSO · TECENTRIQ · TECVAYLI · TEPMETKO · TUKYSA · Tivdak · Trodelvy · ULTOMIRIS · VENCLEXTA · VERZENIO · VPRIV · VYXEOS · Venclexta · Vonjo · Voranigo · XALKORI · XPOVIO · XTANDI · Xtandi · Yescarta · ZEPZELCA · Zoladex
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Geographic Context
Internal medicine physicians in nearby ZIP areas
289
County median income
$58,859
Nearest hospital to ZIP centroid (approximate)
William Beaumont AMG (FT Bliss)
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | NPPES snapshot; verify current record |
| Medicare Enrollment | ✓ PECOS | PECOS snapshot |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not included | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Layman is a mixed practice specialist, with above-average Medicare volume (top 3% in TX), with 15 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Layman experienced with anti-nausea injection (aprepitant)?
Based on Medicare claims data, Dr. Layman performed 8,710 anti-nausea injection (aprepitant) services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Layman receive payments from pharmaceutical companies?
Yes. Dr. Layman received a total of $419,413 from 59 companies across 639 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Layman's costs compare to other internal medicine physicians in El Paso?
Dr. Layman's average Medicare payment per service is $12. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Layman) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
Explore related providers
Same specialty & city
Internal Medicine Physicians in El Paso
Browse internal medicine physicians in El Paso ranked by procedure volume and transparency data.
Highest volume
Top Internal Medicine Physicians in TX
Internal medicine physicians ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Internal Medicine Physicians in TX
Which TX internal medicine physicians receive the most from drug and device companies.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
Regeneron Healthcare Solutions, Inc. Payments to Doctors
See all physicians who received payments from Regeneron Healthcare Solutions, Inc.
About this page
This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology